Achieving an ideal weight may also help improve cardiovascular health and bone health
At 72 weeks, 62.9% of patients in the semaglutide group achieved resolution of steatohepatitis without worsening of fibrosis, compared to 34.3% in the placebo group (estimated difference: 28.%
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using intentionally selected outdated studies to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lillys products
Semaglutide can cause fatigue in some individuals, especially early in treatment
The biggest reason retatrutide may outperform tirzepatide for weight loss comes down to the additional glucagon receptor activity
Advances in receptor de-orphanization, structural biology, and computational modeling have substantially reduced these barriers, warranting renewed evaluation of such systems